Adaptive Biotechnologies Corp.

Adaptive Biotechnologies Corporation is a pioneering biotechnology company at the forefront of immune-driven medicine. The company specializes in decoding and applying the genetics of the adaptive immune system, focusing on the development and commercialization of immune-driven clinical products. Its primary function is to translate the genetic language of the adaptive immune system into clinical products to diagnose, treat, and monitor diseases such as cancer, autoimmune conditions, and infectious diseases. A landmark product of Adaptive Biotechnologies is its immunoSEQ technology, which provides detailed information about the adaptive immune system by sequencing millions of T-cell and B-cell receptors. With its deep expertise in genomics and bioinformatics, Adaptive Biotechnologies plays a vital role in advancing personalized medicine, collaborating extensively with pharmaceutical companies and research organizations. By leveraging its proprietary platform, the company aims to empower the healthcare industry with insights that lead to innovative diagnostic and therapeutic solutions, thereby reinforcing its significant position in the realm of biotechnological advancements.